February 3, 2023
Takeda Pharmaceutical’s April-December revenue surged 13.9% year on year, driven by upbeat performances of its key products such as Entyvio (vedolizumab) and foreign exchange gains, countering a pullback from its one-time income a year ago tied to its diabetes divestiture...read more